Senior Vice President-Protein Platforms · BIO-TECHNE Corp (TECH)

Robert Gavin

A named executive officer of BIO-TECHNE in every fiscal year CompBrief holds from FY2016 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$1,374,490

Salary $393,750Stock awards $162,490

FY2017: $1,215,239

4th of 6 named executive officers at BIO-Techne by FY2018 total.

6 named officers on file for BIO-TECHNE, FY2018

Robert Gavin’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • TECH’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how BIO-TECHNE’s whole pay program stands against its peers

  • BIO-TECHNE’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TECH→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed September 11, 2018 (DEF 14A).

Free

Get Robert Gavin’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Robert Gavin compensation by year

BIO-TECHNE Summary Compensation Table · all 3 fiscal years held
In US dollars, as BIO-TECHNE reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018
Salary$350,000$375,000$393,750
Bonus$0$0$0
Stock awards$108,490$150,015$162,490
Option awards$342,938$449,909$487,488
Non-equity incentive$136,278$226,426$322,662
Pension and deferred compensation$0$0$0
All other$5,250$13,889$8,100
Total$942,956$1,215,239$1,374,490

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIO-TECHNE Corp DEF 14A filed September 11, 2018, accession 0001437749-18-016854, and prior-year filings. Open the filing on EDGAR.

How this page was built: the BIO-TECHNE Corp filed document, accession 0001437749-18-016854. Every figure is read from that document and cited to the page and table it appears in. Filed September 11, 2018.

$943K
$1.2M
$1.4M
FY16
FY17
FY18
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
PSU2,111$312,322—
PSU1,949$288,355—
PSU1,500$221,925—
Option16,667—$93.32
Option9,375—$108.49
Option13,028—$106.59
Option10,742—$125.05
Option1,250—$90.25
Option6,250—$108.49
Option13,028—$106.59
Option14,323—$125.05
Option2,500—$93.32

Per the Outstanding Equity Awards at Fiscal Year-End table in BIO-TECHNE Corp's FY2018 proxy; value at the fiscal year-end close, as the company printed it.

BIO-TECHNE’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Charles KummethPresident and CEO$9,664,874
James HippelSenior Vice President of Finance and CFO$2,448,887
David EansorSenior Vice President-Biotechnology$1,591,282
Robert Gavin · this pageSenior Vice President-Protein Platforms$1,374,490
Brenda FurlowSenior Vice President – General Counsel$1,218,202
Kim KeldermanPresident, Diagnostics and Genomics (16)$1,165,256

The full BIO-TECHNE compensation record

free company brief

This page is one person within BIO-TECHNE's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the BIO-TECHNE proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIO-TECHNE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Robert Gavin's compensation dossier · One-time report. No refunds.